What is Liquid Biopsy?  

    Cancer detection and monitoring method

    Liquid Biopsy, also known as fluid biopsy, is a significant branch of in vitro diagnosis that is primarily based on blood or other body fluid for disease analysis and monitoring, such as cancer. With a simple blood draw, circulating tumor biomarkers in the blood sample provide information on tumor progression and treatment efficacy, and guiding personalized precision medication direction. Compared with traditional tissue biopsy, liquid biopsy has provided additional benefits of real-time monitoring, avoid unrepresentative sampling in heterogenous tumor, and provides comprehensive clinical information.

    Liquid Biopsy is a branch of in vitro diagnostics that analyses and diagnoses diseases such as cancer through the use of body liquids like blood or urine. It was rated as one of the “Breakthrough Technologies 2015” by MIT Technology Review.

    Compared to traditional tissue biopsy, liquid biopsy is equipped with unique advantages like real-time monitoring, ability to overcome tumor heterogeneity, and comprehensive diagnostic information. Currently, in clinical researches, liquid biosy mainly includes tests for CTC (Circulating Tumor Cell), ctDNA (Circulating Tumor DNA), exosomes, and Circulating miRNA etc. In comparison to traditional methods like observation of clinical symptoms or diagnostic imaging, using liquid biopsy can predict the risk of cancer earlier, enabling “Early discovery, early screening, early treatment”.

What is Circulating miRNA?

microRNAs or miRNAs are small RNA molecules that are non-coding and have important effects on gene expression, often inhibitory.  By binding to mRNAs in the cells, the microRNAs inhibit DNA functioning, thus affecting important life functions in a cell. In many cancer types, miRNAs production is upregulated, converting an ordinary cell into a cancerous one. Additionally, these miRNAs can be transported outside the cell, in the tumour environment, in sacs/vesicles called 'exosomes'. The presence of a high number of exosomal miRNAs has been associated with the spread of certain types of cancer in the body. Isolation and detection of miRNAs from a patient’s blood can help in early cancer diagnosis, without the need for invasive surgeries.

What is Circulating Tumor Cell (CTC)?

Circulating tumor cell (CTCs) are the cancer cells that have detached from the primary tumor or metastatic tumor into circulatory system during tumor progression or metastases. CTC provides comprehensive information of cancer in cellular, genetics and protein levels. Hence, CTC detection is an effective tool for earlier detection, evaluation of therapeutic efficacy, individual precision medicine selection, drug resistance detection, earlier tumor recurrence evaluation and real-time monitoring of cancer.

How can we detect CTCs in blood?

Cellomics CTC detection Platform - New generation of CTC viable Cell Sorting.

The CTC detection platform has employed the leading microfluidic chip technology that select CTCs extensively by cell size, cell shape and multiple surface biomarkers. This technology has combined the physical, chemical and biological properties of CTCs to uphold the high sensitivity, high specificity and high accuracy of CTC detection.


What is the bottleneck of early cancer detection?

At present, common examination methods include imaging detection and surgical removal of the patient’s tumor tissue for laboratory tests is necessary to determine whether a patient has cancer.

There is also the liquid biopsy method to determine whether a person has cancer by testing the protein markers secreted by the tumor in the blood, but the sensitivity of the relevant technology is generally only 50%-60% does not belong to accurate detection.

How could we help  ?

Our early cancer screening products have greatly improved the accuracy of liquid biopsy, with over 90% specificity and sensitivity. The platform can even detect cancer 3 to 6 months earlier than imaging tests. Even if the patient’s tumor is as small as 0.1mm and has not yet been diagnosed as cancer through imaging, it can be detected in 5 minutes using our 4 ml blood test. The CTC sorting speed is the fastest in the world with this principle technology. Since our technology can help in the early cancer screening, patients can be treated as soon as possible and will not miss the best time for cancer treatment.

Our Solution

Our Solution


○ The CTC PreDx kit provides all the reagents for

   CTC counting. This kit is recommended for test

   of general public or high risk individuals for

   early detection of cancer and cancer progression


Buffer Solution

Wash Buffer

Blocking Buffer

Fixation Buffer

Staining Solution C - uses antibody CD45 to distinguish white blood cells and CTCs.

Staining Solution D - uses antibody DAPI to stain cells.

The reagent in this kit is enough for 20 CTC tests.

 Early detection

Rack, B., Schindlbeck, C., Jückstock, J., et al. (2014). Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. Journal of the National Cancer Institute, 106(5), dju066. https://doi.org/10.1093/jnci/dju066

Franken, B., de Groot, M. R., Mastboom, W. J., et al. (2012). Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast cancer research : BCR, 14(5), R133. https://doi.org/10.1186/bcr3333

Kuo, J. F., Lin, W. L., & Han, C. P. (2011). Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer, 117(11), 2578–2579. https://doi.org/10.1002/cncr.26089

Yannoutsos, A., Fontaine, M., Galloula, A. et al. (2019). Peripheral arterial disease and systematic detection of circulating tumor cells: rationale and design of the DETECTOR prospective cohort study. BMC cardiovascular disorders, 19(1), 212. https://doi.org/10.1186/s12872-019-1193-1

Ilie, M., Hofman, V., Long-Mira, E., et al. (2014). "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PloS one, 9(10), e111597. https://doi.org/10.1371/journal.pone.0111597

Thery, L., Meddis, A., Cabel, L., et al. (2019). Circulating Tumor Cells in Early Breast Cancer. JNCI cancer spectrum, 3(2), pkz026. https://doi.org/10.1093/jncics/pkz026

Our CTC platform can capture living Circulating Tumor Cells (CTC), shown here using high throughput imagaing. 



CTC 100 Sorter





The Team




Contact Us

Email: info@cellomicsbio.com

Tel: +86-0755-28378001

Copyright © 2020 Cellomics All Rights Reserved

Copyright © 2020 Cellomics All Rights Reserved